A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer

被引:75
作者
Chiva, Luis M. [1 ]
Gonzalez-Martin, Antonio [1 ]
机构
[1] MD Anderson Canc Ctr Madrid, Madrid, Spain
关键词
Ovarian cancer; HIPEC; Cytoreduction; Survival; ADVANCED-STAGE OVARIAN; PHASE-III TRIAL; EPITHELIAL OVARIAN; CYTOREDUCTIVE SURGERY; PERITONEAL CARCINOMATOSIS; NEOADJUVANT CHEMOTHERAPY; SYSTEMIC CHEMOTHERAPY; PROGNOSTIC-FACTORS; RANDOMIZED-TRIAL; IV OVARIAN;
D O I
10.1016/j.ygyno.2014.11.072
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Our objective was to review the published experiences of the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer with a focus on survival outcomes. Methods. A search of the PubMed database (2008-2014) for articles specifically addressing the topic "HIPEC and ovarian cancer" was performed. We found a total of 22 publications that included 1450 patients. A final group of eleven studies (248 patients with advanced ovarian cancer) and eight publications (499 patients with recurrent sensitive ovarian cancer) that included information about survival were reviewed. Results. Among patients with primary ovarian cancer who were treated with primary debulldng and HIPEC, the weighted median overall survival was 37.3 months (range 27-78), the median disease-free survival was 14.4 months (range 12-30), and the 5-yr-survival rate was 40% (range 28-72). In the recurrent cohort, the overall survival after HIPEC was 365 months (range 23-62), and the median disease-free survival was 20.2 months (range 11-29). The rates of severe morbidity were 25 and 19% in the primary and recurrent groups, respectively. Conclusion. Although randomized trials are ongoing, the recently published retrospective data regarding the use of HIPEC for primary advanced and for recurrent ovarian cancer do not indicate any apparent advantage of this treatment in terms of the survival outcomes in these patients. Therefore, HIPEC cannot be considered a standard treatment and should not be offered outside of clinical trials. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:130 / 135
页数:6
相关论文
共 58 条
[1]   OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].
Aghajanian, Carol ;
Blank, Stephanie V. ;
Goff, Barbara A. ;
Judson, Patricia L. ;
Teneriello, Michael G. ;
Husain, Amreen ;
Sovak, Mika A. ;
Yi, Jing ;
Nycum, Lawrence R. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045
[2]   EFFECT OF HYPERTHERMIA ON THE NUMBER OF PLATINUM ATOMS BINDING TO DNA OF HELA-CELLS TREATED WITH PT-195M-RADIOLABELED CIS-DIAMINEDICHLOROPLATINUM(II) [J].
AKABOSHI, M ;
TANAKA, Y ;
KAWAI, K ;
AKUTA, K ;
IMASUNAGA, S ;
ONO, K .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1994, 66 (02) :215-220
[3]  
ALBERTS DS, 1980, JNCI-J NATL CANCER I, V65, P455
[4]  
[Anonymous], GYNECOL ONCOL
[5]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[6]   Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients [J].
Bakrin, N. ;
Bereder, J. M. ;
Decullier, E. ;
Classe, J. M. ;
Msika, S. ;
Lorimier, G. ;
Abboud, K. ;
Meeus, P. ;
Ferron, G. ;
Quenet, F. ;
Marchal, F. ;
Gouy, S. ;
Morice, P. ;
Pomel, C. ;
Pocard, M. ;
Guyon, F. ;
Porcheron, J. ;
Glehen, O. .
EJSO, 2013, 39 (12) :1435-1443
[7]  
BARLOGIE B, 1980, CANCER RES, V40, P1165
[8]   Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].
Bookman, Michael A. ;
Brady, Mark F. ;
McGuire, William P. ;
Harper, Peter G. ;
Alberts, David S. ;
Friedlander, Michael ;
Colombo, Nicoletta ;
Fowler, Jeffrey M. ;
Argenta, Peter A. ;
De Geest, Koen ;
Mutch, David G. ;
Burger, Robert A. ;
Swart, Ann Marie ;
Trimble, Edward L. ;
Accario-Winslow, Chrisann ;
Roth, Lawrence M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425
[9]   Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer [J].
Carrabin, N. ;
Mithieux, F. ;
Meeus, P. ;
Tredan, O. ;
Guastalla, J. -P. ;
Bachelot, T. ;
Labidi, S. I. ;
Treilleux, I. ;
Rivoire, M. ;
Ray-Coquard, I. .
BULLETIN DU CANCER, 2010, 97 (04) :E23-E32
[10]   Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients [J].
Cascales-Campos, P. ;
Gil, J. ;
Gil, E. ;
Feliciangeli, E. ;
Lopez, V. ;
Gonzalez, A. Gil ;
Ruiz-Pardo, J. ;
Nieto, A. ;
Parrilla, P. .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2014, 179 :88-92